Navigation Links
NeuroSigma, Inc. Retains CCG Investor Relations
Date:4/4/2011

LOS ANGELES, April 4, 2011 /PRNewswire/ -- NeuroSigma, Inc. ("NeuroSigma"), a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, today announced that it has retained CCG Investor Relations to design and execute its strategic communications and investor relations campaign.

"We look forward to working closely with CCG to establish and enhance our profile in the investment community and with all our stakeholders," said Lodwrick M. Cook, Chairman of NeuroSigma.

"Given CCG's track record of professional experience representing a wide spectrum of high-growth, U.S. companies, we are confident that our new partnership will help us achieve those goals," added Dr. Leon Ekchian, President and CEO of NeuroSigma.

Founded by experts in business management and the healthcare industry, NeuroSigma has a growing pipeline of therapies in clinical trials targeting epilepsy, depression, post-traumatic stress disorder (PTSD), and obesity, among others.  NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials at the University of California, Los Angeles (UCLA) and is currently utilizing two distinct therapy platforms:

Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at UCLA and exclusively licensed to NeuroSigma.

Deep Brain Stimulation (DBS) – NeuroSigma is supporting the development of new therapies for this platform, which was originally pioneered in France for the treatment of essential tremor and Parkinson's disease.

"We are very pleased to be working with NeuroSigma," said William Coffin, Chairman of CCG Investor Relations.  "At a time when translating important medical research from 'lab bench to bedside' has never been more valuable, NeuroSigma is providing that expertise, working with the very best at institutions like UCLA and bringing their pioneering work to the marketplace for commercialization.  The Company is initially focused on several very important conditions, including epilepsy, which affects 3 million people in the United States and over 50 million worldwide, and major depression, affecting over 18 million American adults and over 120 million worldwide.  With its current team and strong development processes in place, the Company is well positioned for the future."

About NeuroSigma

NeuroSigma is a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice.  Currently we have a specific focus on neuromodulation.  NeuroSigma employs two therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed a significant intellectual property portfolio, primarily licensed from the University of California, Los Angeles on a world-wide exclusive basis, including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS.  More information about NeuroSigma is online at http://www.neurosigma.com/

About CCG Investor Relations

CCG is a leading global investor relations and strategic communications consulting firm.  In business for more than 30 years, the agency provides a complete range of strategic and investor communications, through our global network to over 100 clients across multiple capital markets.  CCG has been awarded a number of industry honors for its handling of complex investor relations communications matters.  The agency's corporate headquarters is in Los Angeles with additional offices in New York, Beijing, Shanghai, Hong Kong, London, and Tel Aviv.  For further information, contact CCG directly, or visit the Company's web site at http://www.ccgir.com/


'/>"/>
SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm
2. Dehaier Medical Retains The Piacente Group as Strategic Investor Relations Consulting Firm
3. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
4. Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts
5. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
6. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
7. Anadys Retains Lazard as Strategic Advisor
8. Connectyx Retains Services of CP Capital Securities as It Expands Its Presence in the $5 Billion US Electronic Health Record Market
9. China Pharma Holdings, Inc. Retains CCG Investor Relations
10. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
11. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  BTL Aesthetics today announced the release of ... ME device was effectively redesigned for more efficient, ... tissue. The result: Significantly better outcomes in abdominal ... ME versus BTL Vanquish. "We are ... patients with the most highly-advanced devices on the ...
(Date:12/6/2016)... 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" or ... today that it entered into collaboration with Takeda ... the treatment of NASH and other gastrointestinal (GI) ... LUNAR™ and UNA Oligomer chemistry. The financial terms ... commitment to and expertise in GI disorders, we ...
(Date:12/6/2016)... 6, 2016 A new study released today ... 340B) projects the 340B Drug Pricing Program will continue to ... it is expected to exceed $23 billion in total purchases ... purchases surpass current Medicare Part B drug reimbursement purchases over ... – based on analysis of data on total drug purchases ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... "Hacking into my ... had described him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in ... published by Wyston Books, Inc. These novels narrate the lives of a ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum ... risk of serious health problems, such as cardiovascular illness, according to research cited ... Beverly Hills Periodontics & Dental Implant Center notes that the correlation between periodontal ...
(Date:12/6/2016)... ... ... An inventor, from Talladega, Ala., thought there needed to be a more ... , The SLING-VEST provides an effective way to support and align the arm or ... result, it helps to reduce discomfort and shifting. The invention features an effective design ...
(Date:12/6/2016)... ... ... Mount Sinai Health System today announced the creation of the Medical Modeling ... order 3D models for their cases. Virtual reality, simulation, and 3D printing services ... resource will be the first of its kind catering to the unique patient-specific modeling ...
(Date:12/6/2016)... Scottsdale, Arizona (PRWEB) , ... December 06, 2016 , ... ... less than fIve days after launch. Almost 200 backers pledged more than $25,000 ... life-changing technology. , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, ...
Breaking Medicine News(10 mins):